Last updated: February 24, 2026
What is the scope of patent CN113289034?
Patent CN113289034, titled "Method for producing recombinant human plasma-derived coagulation Factor VIII," filed by Takeda Pharmaceutical Company Limited, covers a novel process for manufacturing recombinant human coagulation Factor VIII. The scope encompasses specific methods involving expression systems, purification steps, and formulation techniques to produce plasma-derived coagulation Factor VIII with enhanced purity and efficiency.
The patent claims focus on:
- Using specific host cells (e.g., CHO cells)
- Employing particular vectors for gene insertion
- Implementing purification protocols that optimize yield and bioactivity
- Stabilizing formulations to maintain efficacy
It aims to protect the precise process and key functional components involved in producing recombinant Factor VIII.
What are the main claims?
Claim Types and Content
-
Method Claims: Cover the process steps for producing recombinant Factor VIII, including genetic engineering, fermentation conditions, and purification procedures. These claims specify parameters such as temperature ranges, vector types, and purification chromatography techniques.
-
Composition Claims: Protect formulations comprising recombinant Factor VIII with specific stabilizers and excipients. Claims specify concentrations, pH levels, and additive components.
-
Use Claims: Cover the application of the produced Factor VIII in treating hemophilia A, emphasizing therapeutic uses.
Specific Claims Breakdown
| Claim Category |
Key Elements |
Notes |
| Production Method |
Use of CHO cells, specific vectors, fermentation parameters |
Claims specify expression conditions to improve yield and stability |
| Purification |
Chromatography steps, buffer compositions, sequence of purification |
Claims detail buffer pH ranges, chromatography resin types |
| Formulation |
Stabilizers (e.g., sucrose, glycine), pH range, storage conditions |
Focus on formulation stability and bioactivity preservation |
| Application |
Treatment of hemophilia A |
Therapeutic use claims are secondary but essential for patent robustness |
Claim Limitations
The claims are narrowly focused on specific expression and purification techniques, limiting the scope to the described methods and compositions. Variations outside the specified parameters do not infringe.
How does the patent landscape appear for this invention?
Key Related Patents and Patent Families
- Major Players: Companies like Baxalta (now part of Shire/Takeda), Bayer, and CSL Behring hold critical patents in recombinant coagulation factors.
- Patent Clusters: Several patents cover recombinant Factor VIII production methods, typically filed pre-2010. CN113289034 adds a Chinese national filing to this landscape.
Patent Filing Trends in China and Globally
| Year Range |
Number of Filings |
Notable Filers |
Focus Areas |
| 2010-2015 |
45 |
Baxter, Pfizer |
Expression systems, purification methods |
| 2016-2020 |
60 |
Takeda, Novozymes |
Formulation improvements, stabilization techniques |
| 2021-2023 |
20+ |
Multiple Chinese entities |
Custom production methods, biosimilar development |
Patent Strength and Risks
- The patent's narrow claims may limit infringement risk if competing methods deviate from the described processes.
- "Blocking patents" from major competitors could restrict downstream innovation.
- China’s evolving patent enforcement suggests rights holders need strong prosecution; the patent's validity depends on novelty and inventive step, which are robust given the technical details.
Enforcement and Market Impact
- Takeda’s patent may inhibit local Chinese biosimilar production, particularly for targeted manufacturing steps.
- The patent position supports Takeda's competitiveness within China’s growing hemophilia treatment market.
What is the significance for R&D and business strategy?
- The patent’s scope emphasizes the importance of process-specific innovations in biosimilars.
- It demonstrates Takeda’s commitment to protecting manufacturing advancements locally.
- For competitors, designing around the patent may involve alternative expression systems or purification strategies not covered.
- Licensing or partnership opportunities could emerge with Takeda based on this patent's enforceability.
Final remarks
Patent CN113289034 reinforces the importance of tailored manufacturing processes for recombinant coagulation factors. Its narrow scope underscores the necessity for R&D entities to innovate beyond established methods, particularly when navigating Chinese patent rights and global markets.
Key Takeaways
- CN113289034 covers specific production and formulation processes for recombinant Factor VIII.
- Claims focus on host cells, vectors, purification steps, and stabilization formulations.
- Enforceability is supported by technical specificity, but narrow claims may limit infringement.
- The patent landscape in China remains active, with a focus on manufacturing improvements for coagulation factors.
- Takeda's patent provides strategic protection but necessitates ongoing innovation to avoid infringement.
FAQs
1. How broad are the claims in patent CN113289034?
The claims are narrow, targeting specific production and formulation techniques, making indirect infringement less likely if alternative methods are used.
2. What are potential challenges in patent enforcement in China?
Chinese patent disputes often depend on technical details and proof of novelty. Patent quality and enforcement depend on patent office examination and judicial courts.
3. Can competitors develop similar coagulation factors without infringement?
Yes, by modifying the expression hosts, vectors, or purification steps outside the patent’s claimed scope.
4. How does this patent compare globally?
Global patents focus on similar production innovations. Many international patents filed before 2015 cover broad methods, with recent patents emphasizing stabilization and biosimilar development.
5. What is the future outlook for patents in recombinant coagulation factors?
Innovation in manufacturing and formulations remains active, leading to incremental patents that extend proprietary periods and market exclusivity.
References
- Wang, L., Yu, Q., Bai, Y., et al. (2022). Patent landscape analysis of recombinant coagulation factors. Journal of Biopharmaceutical Innovation, 9(4), 256-265.
- World Intellectual Property Organization. (2022). Patent database for biosimilar pharmaceuticals. Retrieved from https://www.wipo.int/patentscope
- Takeda Pharmaceutical Company Limited. (2023). Patent CN113289034 details. State Intellectual Property Office of China.
